Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
giclanfentrine + glycopyrronium bromide
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Giclanfentrine + glycopyrronium bromide (TQC3721 + glycopyrronium bromide) is an investigational inhaled combination therapy being developed for the treatment of chronic obstructive pulmonary disease (COPD). The combination consists of giclanfentrine (TQC3721), a novel small-molecule dual phosphodiesterase 3 and 4 (PDE3/4) inhibitor developed by Chia Tai Tianqing (CTTQ), and glycopyrronium bromide (glycopyrrolate), a long-acting muscarinic antagonist (LAMA). Giclanfentrine provides both bronchodilation (via PDE3 inhibition) and anti-inflammatory effects (via PDE4 inhibition), while glycopyrronium bromide acts as an anticholinergic bronchodilator by blocking muscarinic M3 receptors. In clinical studies, the combination of TQC3721 dry powder inhaler (DPI) and glycopyrronium bromide demonstrated bronchodilator effects comparable to indacaterol/glycopyrronium bromide with good tolerability. AstraZeneca holds the exclusive rights to develop and commercialize TQC3721 outside of China, while CTTQ retains rights within China.
- Other names
- giclanfentrine + glycopyrrolateglyberlam + TQC3721TQC3721 + glyberlamTQC3721 + glycopyrrolateTQC3721 + glycopyrronium bromideTQC3721 DPI + glycopyrrolateTQC3721 DPI + glycopyrronium bromide
02
Targets
CHRM3 (M3)PDE4APDE4B (3',5'-cyclic-AMP phosphodiesterase 4B)PDE4C (Phosphodiesterase 4C)PDE4D (Phosphodiesterase 4D)PDE3B (Phosphodiesterase 3B)PDE3A (Phosphodiesterase 3A)
Beyond the preview
Go deeper on giclanfentrine + glycopyrronium bromide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on giclanfentrine + glycopyrronium bromide.